Chronic respiratory diseases (asthma, COPD, cystic fibrosis) require safe, sterile, and optimized formulations for inhaled administration. There is increasing demand for more tolerable, preservative-free solutions adapted to current nebulization practices.
Unither has developed unique expertise in sterile forms for inhalation, particularly through global-scale mastery of Blow-Fill-Seal (BFS). This closed and aseptic technology allows the production of sterile single doses that are perfectly suited to nebulization, offering high stability and optimal tolerance.
We also support laboratories in the development of multi-dose respiratory solutions and suspensions, with or without preservatives, adapted to international regulatory requirements (EMA, FDA, ANVISA, NMPA).